Anti-MICA Antigen Binding Fragments for Environmental and Health Applications

Publication ID: 24-11857571_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Anti-MICA Antigen Binding Fragments for Environmental and Health Applications,” Published Technical Disclosure No. 24-11857571_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857571_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,571.

Summary of the Inventive Concept

This inventive concept leverages the core technology of anti-MICA antigen binding fragments to develop novel solutions for environmental monitoring, health diagnostics, and food safety.

Background and Problem Solved

The original patent disclosed anti-MICA antigen binding fragments for immunotherapy applications. However, the limitations of the original patent lie in its narrow focus on cancer treatment. The new inventive concept addresses the need for innovative solutions in environmental monitoring, health diagnostics, and food safety by applying the core technology to these entirely new fields.

Detailed Description of the Inventive Concept

The new inventive concept comprises systems and methods utilizing anti-MICA antigen binding fragments for detecting and quantifying pollutants in air, waterborne pathogens, biomarkers for neurological disorders, heavy metals in soil, and contaminants in food products. These fragments can be engineered to bind specifically to target molecules, facilitating their detection and removal. The inventive concept's components include the anti-MICA antigen binding fragments, detection systems, and methods for sample preparation and analysis.

Novelty and Inventive Step

The new claims introduce novel applications and use cases for anti-MICA antigen binding fragments, which were not originally considered in the patent. The inventive step lies in the unexpected use of these fragments in environmental monitoring, health diagnostics, and food safety, demonstrating a non-obvious extension of the original technology.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different antigen binding fragments, detection systems, or sample preparation methods. Variations could also involve the integration of machine learning algorithms for data analysis or the development of portable detection devices.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the environmental monitoring, health diagnostics, and food safety industries. The market for these applications is substantial, with growing demands for innovative solutions to address pressing environmental and health concerns.

Field of Art

Biotechnology and molecular biology, specifically focused on antigen binding fragments, chimeric antigen receptors (CARs), and diagnostic/detection technologies involving protein engineering

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in molecular biology or biotechnology, experienced in protein engineering, antibody fragment design, and diagnostic technology development, familiar with techniques for adapting molecular binding technologies to various detection and monitoring applications

Obviousness Rationale

A person having ordinary skill in the art would recognize that the anti-MICA antigen binding fragments disclosed in the source patent possess inherent versatility for detection and binding applications across multiple domains. The specific molecular characteristics of these fragments naturally lend themselves to adaptation in environmental monitoring, diagnostic, and detection technologies. The core binding mechanism of the anti-MICA fragments can be readily translated into diverse detection systems with predictable and expected results.

Obvious Combinations & Variations

Source Patent Element
Anti-MICA antibody fragments with specific binding capabilities
PTD Variation
Application of fragments to detect environmental pollutants in air and soil
Obviousness Reasoning
Known protein engineering techniques allow predictable adaptation of binding fragments to detect various molecular targets, representing a standard design choice in biotechnology
Source Patent Element
Chimeric antigen receptor (CAR) technology involving MICA-specific binding
PTD Variation
Extending fragment usage to pathogen detection and removal in water systems
Obviousness Reasoning
Molecular binding principles are transferable across different detection contexts, with a PHOSITA expecting successful adaptation based on established protein engineering methodologies
Source Patent Element
Antigen binding fragment with specific molecular recognition capabilities
PTD Variation
Diagnostic applications for detecting neurological disorder biomarkers
Obviousness Reasoning
Biomarker detection represents a predictable and logical extension of molecular binding fragment technologies, utilizing standard diagnostic engineering approaches
Source Patent Element
Single chain Fv (scFv) fragment with modular design
PTD Variation
Food safety monitoring through contaminant detection
Obviousness Reasoning
Molecular fragment modularity inherently supports diverse detection applications, representing an expected technological progression for skilled practitioners
Source Patent Element
Antibody fragment with specific binding characteristics
PTD Variation
Heavy metal detection and removal systems
Obviousness Reasoning
Protein engineering principles support predictable adaptation of binding fragments across different molecular targeting scenarios
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857571 and the disclosed variations, a person having ordinary skill in the art would find the proposed applications of anti-MICA antigen binding fragments to environmental monitoring, diagnostic, and detection technologies to be obvious extensions of the existing molecular binding technology. The inherent versatility of the molecular fragments, combined with standard protein engineering techniques, renders the proposed variations predictable and non-inventive under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,571
TitleAnti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
Assignee(s)The Trustees of Dartmouth College